Share
274 Posts.
lightbulb Created with Sketch. 66
clock Created with Sketch. 04/04/18
09:58
Share
Originally posted by valueinvesting
↑
Approximately 8.25 million sales revenue for temcell in fy 2016- not a bad for the start. Waiting for FY 2017 sales figures. I don’t have any concern for the agvhd success . However, i’m bit cautious about the credit sussie analysts comments about possibilities of MSB requiring more data set for back pain and heart failure for approval. Is this assertion true? My thinking is 21st century cure act would enable mesoblast to file for approval if existing phase 3 trial is successful and if necessary MSB might require to submit post product launch data. Guys, what are your take on this?
Expand
I find it interesting that the CS analyst has already made up their mind with no data to work from.
